{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:03:38Z","timestamp":1765487018077,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"DOI":"10.7759\/cureus.98987","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:57:17Z","timestamp":1765486637000},"source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Switching to an Integrase Inhibitor-Based Single-Tablet Regimen in Adults Living With HIV and Sustained Virological Suppression on Outdated Antiretroviral Therapies"],"prefix":"10.7759","author":[{"given":"Giorgio","family":"Tiecco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Scarvaglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Cesanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016","volume":"3","author":"Marcus JL","year":"2020","unstructured":"Marcus JL, Leyden WA, Alexeeff SE, et al.. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open. 2020, 3:e207954. 10.1001\/jamanetworkopen.2020.7954","journal-title":"JAMA Netw Open"},{"key":"ref2","unstructured":"2024 Global AIDS report \u2014 the urgency of now. AIDS at a crossroads. (2024). Accessed: 15 July, 2025: https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/global-aids-update-2024."},{"key":"ref3","unstructured":"EACS guidelines, version 12.1. (2023). Accessed. 15 July, 2025: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis","volume":"27","author":"Shubber Z","year":"2013","unstructured":"Shubber Z, Calmy A, Andrieux-Meyer I, et al.. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013, 27:1403-12. 10.1097\/QAD.0b013e32835f1db0","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S107152","article-title":"Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele","volume":"10","author":"Panagopoulos P","year":"2017","unstructured":"Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D. Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele. Pharmgenomics Pers Med. 2017, 10:205-8. 10.2147\/PGPM.S107152","journal-title":"Pharmgenomics Pers Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.4.427","article-title":"Etravirine for the treatment of HIV infection","volume":"6","author":"Seminari E","year":"2008","unstructured":"Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2008, 6:427-33. 10.1586\/14787210.6.4.427","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225381","article-title":"Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: a European survey","volume":"14","author":"De Luca A","year":"2019","unstructured":"De Luca A, Pezzotti P, Boucher C, et al.. Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: a European survey. PLoS One. 2019, 14:e0225381. 10.1371\/journal.pone.0225381","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/11204950-000000000-00000","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV-1 infection","volume":"70","author":"Croxtall JD","year":"2010","unstructured":"Croxtall JD, Perry CM. Lopinavir\/ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010, 70:1885-915. 10.2165\/11204950-000000000-00000","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks SG","year":"2011","unstructured":"Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011, 62:141-55. 10.1146\/annurev-med-042909-093756","journal-title":"Annu Rev Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective","volume":"28","author":"Carr A","year":"2023","unstructured":"Carr A, Mackie NE, Paredes R, Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective. Antivir Ther. 2023, 28:13596535231201162. 10.1177\/13596535231201162","journal-title":"Antivir Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"Grennan JT","year":"2012","unstructured":"Grennan JT, Loutfy MR, Su D, et al.. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012, 205:1230-8. 10.1093\/infdis\/jis104","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of virologic failure and HIV drug resistance","volume":"33","author":"McCluskey SM","year":"2019","unstructured":"McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance. Infect Dis Clin North Am. 2019, 33:707-42. 10.1016\/j.idc.2019.05.004","journal-title":"Infect Dis Clin North Am"},{"key":"ref13","unstructured":"Stanford University, HIV drug resistance database . (2025). Accessed. 15 July, 2025: https:\/\/hivdb.stanford.edu\/."},{"key":"ref14","unstructured":"Research electronic data capture (REDCap)- a metadata-driven methodology and workflow process for providing translational research informatics support. (2025). Accessed. 15 July, 2025: https:\/\/project-redcap.org\/."},{"key":"ref15","unstructured":"Mice. Multivariate imputation by chained equations in R. (2025). Accessed: 15 July, 2025: https:\/\/www.jstatsoft.org\/article\/view\/v045i03."},{"key":"ref16","unstructured":"Normalization. a preprocessing stage. (2015). Accessed: 15 July, 2025: https:\/\/arxiv.org\/abs\/1503.06462."},{"key":"ref17","article-title":"Biometrika","author":"Biometrika Trust","year":"1993","unstructured":"Biometrika Trust. Biometrika.  Oxford University Press, Oxford, UK; 1993."},{"key":"ref18","article-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin DB","year":"2009","unstructured":"Rubin DB. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons, Hoboken, NJ; 2009."},{"key":"ref19","unstructured":"The jamovi project. (2025). Accessed. 15 July, 2025: https:\/\/www.jamovi.org."},{"key":"ref20","unstructured":"The R Project for Statistical Computing. (2025). Accessed. 15 July, 2025: https:\/\/www.R-project.org\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002071","article-title":"Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the United States","volume":"81","author":"Crane HM","year":"2019","unstructured":"Crane HM, Nance RM, Heckbert SR, et al.. Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the United States. J Acquir Immune Defic Syndr. 2019, 81:e141-7. 10.1097\/QAI.0000000000002071","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead059","article-title":"Exploring the link between Gilbert's syndrome and atherosclerotic cardiovascular disease: insights from a subpopulation-based analysis of over one million individuals","volume":"3","author":"Kartoun U","year":"2023","unstructured":"Kartoun U, Fahed AC, Kany S, et al.. Exploring the link between Gilbert's syndrome and atherosclerotic cardiovascular disease: insights from a subpopulation-based analysis of over one million individuals. Eur Heart J Open. 2023, 3:oead059. 10.1093\/ehjopen\/oead059","journal-title":"Eur Heart J Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.11.019","article-title":"HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system","volume":"1842","author":"Reyskens KM","year":"2014","unstructured":"Reyskens KM, Essop MF. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim Biophys Acta. 2014, 1842:256-68. 10.1016\/j.bbadis.2013.11.019","journal-title":"Biochim Biophys Acta"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.083","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure","volume":"72","author":"Alvi RM","year":"2018","unstructured":"Alvi RM, Neilan AM, Tariq N, et al.. Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure. J Am Coll Cardiol. 2018, 72:518-30. 10.1016\/j.jacc.2018.04.083","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.23000002","article-title":"The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis","volume":"26","author":"Kandeel M","year":"2023","unstructured":"Kandeel M. The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis. AIDS Rev. 2023, 26:136-44. 10.24875\/AIDSRev.23000002","journal-title":"AIDS Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng A","year":"2015","unstructured":"Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015, 79:182-94. 10.1111\/bcp.12403","journal-title":"Br J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae189","article-title":"HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21","volume":"79","author":"Fabeni L","year":"2024","unstructured":"Fabeni L, Armenia D, Abbate I, et al.. HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21. J Antimicrob Chemother. 2024, 79:2152-62. 10.1093\/jac\/dkae189","journal-title":"J Antimicrob Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle T","year":"2015","unstructured":"Doyle T, Dunn DT, Ceccherini-Silberstein F, et al.. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 2015, 70:3080-6. 10.1093\/jac\/dkv243","journal-title":"J Antimicrob Chemother"},{"key":"ref29","unstructured":"Clinical guidelines. (2025). Accessed. 15 July, 2025: https:\/\/bhiva.org\/clinical-guidelines\/."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13734","article-title":"Implementation of patient-reported outcomes for people living with HIV: insights from patients and healthcare providers in a Danish outpatient clinic","volume":"26","author":"Rodkj\u00e6r L\u00d8","year":"2025","unstructured":"Rodkj\u00e6r L\u00d8, Storgaard M, Schougaard LM. Implementation of patient-reported outcomes for people living with HIV: insights from patients and healthcare providers in a Danish outpatient clinic. HIV Med. 2025, 26:319-25. 10.1111\/hiv.13734","journal-title":"HIV Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416863-feasibility-of-switching-to-an-integrase-inhibitor-based-single-tablet-regimen-in-adults-living-with-hiv-and-sustained-virological-suppression-on-outdated-antiretroviral-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:57:19Z","timestamp":1765486639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416863-feasibility-of-switching-to-an-integrase-inhibitor-based-single-tablet-regimen-in-adults-living-with-hiv-and-sustained-virological-suppression-on-outdated-antiretroviral-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.98987","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}